Ocular Therapeutix, Inc. Closes on $23.8 Million Series D Extension
1/28/2013 9:55:40 AM
More...
|
Richard Lindstrom Joins Board of Directors at Ocular Therapeutix, Inc.
11/6/2012 9:11:42 AM
More...
|
Ocular Therapeutix, Inc. Demonstrates Two-Month IOP Reduction With Sustained Release Travoprost for the Treatment of Glaucoma
10/30/2012 9:41:39 AM
More...
|
Ocular Therapeutix, Inc. Completes U.S. Pivotal Clinical Trial Enrollment for ReSure Sealant
9/4/2012 10:48:31 AM
More...
|
Ocular Therapeutix, Inc. Commences Pilot Phase II Travoprost Punctum Plug Study for the Treatment of Glaucoma
8/21/2012 9:48:06 AM
More...
|
Ocular Therapeutix, Inc. Discloses Promising Results for Extended Release Treatment of Glaucoma
7/24/2012 10:01:01 AM
More...
|
Ocular Therapeutix, Inc. Commences a Sustained Release Travoprost Punctum Plug Feasibility Study for Treatment of Glaucoma
5/7/2012 10:53:48 AM
More...
|
Ocular Therapeutix, Inc. Receives IDE Approval to Conduct a Pivotal Clinical Trial for ReSure(TM) Sealant
2/7/2012 9:34:14 AM
More...
|
Ocular Therapeutix, Inc. Grabs $14M in New Round for Eye Therapies
2/3/2011 7:41:32 AM
More...
|
Ocular Therapeutix, Inc. Adds $6 Million to C Round
1/13/2011 7:44:40 AM
More...
|
|